Idorsia Ltd

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NONOF has a market cap of 177.7B. Regarding current trading prices, IDRSF is priced at $4.32, while NONOF trades at $40.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NONOF's P/E ratio is 11.02. In terms of profitability, IDRSF's ROE is +0.10%, compared to NONOF's ROE of +0.61%. Regarding short-term risk, IDRSF is less volatile compared to NONOF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check NONOF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CSLLY has a market cap of 89.8B. Regarding current trading prices, IDRSF is priced at $4.32, while CSLLY trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CSLLY's P/E ratio is 15.06. In terms of profitability, IDRSF's ROE is +0.10%, compared to CSLLY's ROE of +0.08%. Regarding short-term risk, IDRSF is less volatile compared to CSLLY. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CSLLY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, UCBJF has a market cap of 55.5B. Regarding current trading prices, IDRSF is priced at $4.32, while UCBJF trades at $291.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas UCBJF's P/E ratio is 30.77. In terms of profitability, IDRSF's ROE is +0.10%, compared to UCBJF's ROE of +0.15%. Regarding short-term risk, IDRSF is less volatile compared to UCBJF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check UCBJF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, UCBJY has a market cap of 53.7B. Regarding current trading prices, IDRSF is priced at $4.32, while UCBJY trades at $139.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas UCBJY's P/E ratio is 29.73. In terms of profitability, IDRSF's ROE is +0.10%, compared to UCBJY's ROE of +0.15%. Regarding short-term risk, IDRSF is more volatile compared to UCBJY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check UCBJY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ARGNF has a market cap of 49.4B. Regarding current trading prices, IDRSF is priced at $4.32, while ARGNF trades at $781.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ARGNF's P/E ratio is 40.84. In terms of profitability, IDRSF's ROE is +0.10%, compared to ARGNF's ROE of +0.34%. Regarding short-term risk, IDRSF is more volatile compared to ARGNF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ARGNF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CMXHF has a market cap of 44.5B. Regarding current trading prices, IDRSF is priced at $4.32, while CMXHF trades at $92.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CMXHF's P/E ratio is 14.87. In terms of profitability, IDRSF's ROE is +0.10%, compared to CMXHF's ROE of +0.08%. Regarding short-term risk, IDRSF is less volatile compared to CMXHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CMXHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, WXIBF has a market cap of 19.4B. Regarding current trading prices, IDRSF is priced at $4.32, while WXIBF trades at $4.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas WXIBF's P/E ratio is 27.65. In terms of profitability, IDRSF's ROE is +0.10%, compared to WXIBF's ROE of +0.11%. Regarding short-term risk, IDRSF is less volatile compared to WXIBF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check WXIBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, IVBXF has a market cap of 17.7B. Regarding current trading prices, IDRSF is priced at $4.32, while IVBXF trades at $10.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas IVBXF's P/E ratio is 147.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to IVBXF's ROE of +0.05%. Regarding short-term risk, IDRSF is less volatile compared to IVBXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check IVBXF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, WXXWY has a market cap of 17.7B. Regarding current trading prices, IDRSF is priced at $4.32, while WXXWY trades at $8.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas WXXWY's P/E ratio is 25.12. In terms of profitability, IDRSF's ROE is +0.10%, compared to WXXWY's ROE of +0.11%. Regarding short-term risk, IDRSF is less volatile compared to WXXWY. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check WXXWY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GNMSF has a market cap of 16.8B. Regarding current trading prices, IDRSF is priced at $4.32, while GNMSF trades at $271.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GNMSF's P/E ratio is 17.70. In terms of profitability, IDRSF's ROE is +0.10%, compared to GNMSF's ROE of +0.19%. Regarding short-term risk, IDRSF is less volatile compared to GNMSF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check GNMSF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SBMFF has a market cap of 13.6B. Regarding current trading prices, IDRSF is priced at $4.32, while SBMFF trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SBMFF's P/E ratio is 25.33. In terms of profitability, IDRSF's ROE is +0.10%, compared to SBMFF's ROE of +0.11%. Regarding short-term risk, IDRSF is more volatile compared to SBMFF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SBMFF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SBHMY has a market cap of 12.7B. Regarding current trading prices, IDRSF is priced at $4.32, while SBHMY trades at $14.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SBHMY's P/E ratio is 37.37. In terms of profitability, IDRSF's ROE is +0.10%, compared to SBHMY's ROE of +0.11%. Regarding short-term risk, IDRSF is more volatile compared to SBHMY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SBHMY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BRRGF has a market cap of 9.5B. Regarding current trading prices, IDRSF is priced at $4.32, while BRRGF trades at $97.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BRRGF's P/E ratio is -0.48. In terms of profitability, IDRSF's ROE is +0.10%, compared to BRRGF's ROE of -0.97%. Regarding short-term risk, IDRSF is less volatile compared to BRRGF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check BRRGF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, AAVXF has a market cap of 9.2B. Regarding current trading prices, IDRSF is priced at $4.32, while AAVXF trades at $115.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas AAVXF's P/E ratio is -22.11. In terms of profitability, IDRSF's ROE is +0.10%, compared to AAVXF's ROE of -1.65%. Regarding short-term risk, IDRSF is more volatile compared to AAVXF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check AAVXF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ODTC has a market cap of 8B. Regarding current trading prices, IDRSF is priced at $4.32, while ODTC trades at $22,005.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ODTC's P/E ratio is 1.07. In terms of profitability, IDRSF's ROE is +0.10%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, IDRSF is more volatile compared to ODTC. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ODTC's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, AKBLF has a market cap of 7.2B. Regarding current trading prices, IDRSF is priced at $4.32, while AKBLF trades at $35.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas AKBLF's P/E ratio is 37.04. In terms of profitability, IDRSF's ROE is +0.10%, compared to AKBLF's ROE of +0.20%. Regarding short-term risk, IDRSF is less volatile compared to AKBLF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check AKBLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, TRSBF has a market cap of 6.7B. Regarding current trading prices, IDRSF is priced at $4.32, while TRSBF trades at $2.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas TRSBF's P/E ratio is 20.18. In terms of profitability, IDRSF's ROE is +0.10%, compared to TRSBF's ROE of +0.38%. Regarding short-term risk, IDRSF is less volatile compared to TRSBF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check TRSBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, REGMF has a market cap of 6.2B. Regarding current trading prices, IDRSF is priced at $4.32, while REGMF trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas REGMF's P/E ratio is 57.63. In terms of profitability, IDRSF's ROE is +0.10%, compared to REGMF's ROE of +0.27%. Regarding short-term risk, IDRSF is less volatile compared to REGMF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check REGMF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, IDRSF is priced at $4.32, while ABCZF trades at $22.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to ABCZF's ROE of +0.29%. Regarding short-term risk, IDRSF is more volatile compared to ABCZF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ABCZF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, IDRSF is priced at $4.32, while LABFF trades at $90.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas LABFF's P/E ratio is 28.95. In terms of profitability, IDRSF's ROE is +0.10%, compared to LABFF's ROE of +0.23%. Regarding short-term risk, IDRSF is more volatile compared to LABFF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check LABFF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SHJBF has a market cap of 4.3B. Regarding current trading prices, IDRSF is priced at $4.32, while SHJBF trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SHJBF's P/E ratio is -25.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to SHJBF's ROE of -0.14%. Regarding short-term risk, IDRSF is less volatile compared to SHJBF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check SHJBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CAMRF has a market cap of 3.8B. Regarding current trading prices, IDRSF is priced at $4.32, while CAMRF trades at $63.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CAMRF's P/E ratio is 47.24. In terms of profitability, IDRSF's ROE is +0.10%, compared to CAMRF's ROE of +0.19%. Regarding short-term risk, IDRSF is less volatile compared to CAMRF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CAMRF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, TLPPF has a market cap of 3.5B. Regarding current trading prices, IDRSF is priced at $4.32, while TLPPF trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas TLPPF's P/E ratio is -522.50. In terms of profitability, IDRSF's ROE is +0.10%, compared to TLPPF's ROE of -0.02%. Regarding short-term risk, IDRSF is less volatile compared to TLPPF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check TLPPF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ZLDPF has a market cap of 3.4B. Regarding current trading prices, IDRSF is priced at $4.32, while ZLDPF trades at $47.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ZLDPF's P/E ratio is 3.34. In terms of profitability, IDRSF's ROE is +0.10%, compared to ZLDPF's ROE of +0.48%. Regarding short-term risk, IDRSF is less volatile compared to ZLDPF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check ZLDPF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ASPHF has a market cap of 3.2B. Regarding current trading prices, IDRSF is priced at $4.32, while ASPHF trades at $8.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ASPHF's P/E ratio is -16.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to ASPHF's ROE of -0.73%. Regarding short-term risk, IDRSF is more volatile compared to ASPHF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ASPHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GNNSF has a market cap of 3.1B. Regarding current trading prices, IDRSF is priced at $4.32, while GNNSF trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GNNSF's P/E ratio is -5.68. In terms of profitability, IDRSF's ROE is +0.10%, compared to GNNSF's ROE of -0.13%. Regarding short-term risk, IDRSF is more volatile compared to GNNSF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check GNNSF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BRCTF has a market cap of 2.9B. Regarding current trading prices, IDRSF is priced at $4.32, while BRCTF trades at $33.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BRCTF's P/E ratio is 26.21. In terms of profitability, IDRSF's ROE is +0.10%, compared to BRCTF's ROE of +0.52%. Regarding short-term risk, IDRSF is less volatile compared to BRCTF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check BRCTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, IDRSF is priced at $4.32, while MPSYF trades at $73.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, IDRSF's ROE is +0.10%, compared to MPSYF's ROE of -1.84%. Regarding short-term risk, IDRSF is less volatile compared to MPSYF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check MPSYF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ASCLF has a market cap of 2.6B. Regarding current trading prices, IDRSF is priced at $4.32, while ASCLF trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ASCLF's P/E ratio is -48.90. In terms of profitability, IDRSF's ROE is +0.10%, compared to ASCLF's ROE of -0.19%. Regarding short-term risk, IDRSF is less volatile compared to ASCLF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check ASCLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BVNKF has a market cap of 2.4B. Regarding current trading prices, IDRSF is priced at $4.32, while BVNKF trades at $30.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BVNKF's P/E ratio is 11.05. In terms of profitability, IDRSF's ROE is +0.10%, compared to BVNKF's ROE of +0.11%. Regarding short-term risk, IDRSF is more volatile compared to BVNKF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check BVNKF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, INCPF has a market cap of 2.3B. Regarding current trading prices, IDRSF is priced at $4.32, while INCPF trades at $1.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas INCPF's P/E ratio is 25.83. In terms of profitability, IDRSF's ROE is +0.10%, compared to INCPF's ROE of +0.09%. Regarding short-term risk, IDRSF is less volatile compared to INCPF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check INCPF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BVNRY has a market cap of 2.3B. Regarding current trading prices, IDRSF is priced at $4.32, while BVNRY trades at $9.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BVNRY's P/E ratio is 10.40. In terms of profitability, IDRSF's ROE is +0.10%, compared to BVNRY's ROE of +0.11%. Regarding short-term risk, IDRSF is more volatile compared to BVNRY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check BVNRY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GENSF has a market cap of 2.2B. Regarding current trading prices, IDRSF is priced at $4.32, while GENSF trades at $33.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GENSF's P/E ratio is 34.54. In terms of profitability, IDRSF's ROE is +0.10%, compared to GENSF's ROE of +0.10%. Regarding short-term risk, IDRSF is less volatile compared to GENSF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check GENSF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MEOBF has a market cap of 2.2B. Regarding current trading prices, IDRSF is priced at $4.32, while MEOBF trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MEOBF's P/E ratio is -24.29. In terms of profitability, IDRSF's ROE is +0.10%, compared to MEOBF's ROE of -0.14%. Regarding short-term risk, IDRSF is more volatile compared to MEOBF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check MEOBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GLPGF has a market cap of 1.9B. Regarding current trading prices, IDRSF is priced at $4.32, while GLPGF trades at $28.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GLPGF's P/E ratio is -3.50. In terms of profitability, IDRSF's ROE is +0.10%, compared to GLPGF's ROE of +0.11%. Regarding short-term risk, IDRSF is more volatile compared to GLPGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check GLPGF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PHMMF has a market cap of 1.8B. Regarding current trading prices, IDRSF is priced at $4.32, while PHMMF trades at $106.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PHMMF's P/E ratio is 46.29. In terms of profitability, IDRSF's ROE is +0.10%, compared to PHMMF's ROE of +0.35%. Regarding short-term risk, IDRSF is more volatile compared to PHMMF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check PHMMF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ONTTF has a market cap of 1.6B. Regarding current trading prices, IDRSF is priced at $4.32, while ONTTF trades at $1.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ONTTF's P/E ratio is -7.95. In terms of profitability, IDRSF's ROE is +0.10%, compared to ONTTF's ROE of -0.29%. Regarding short-term risk, IDRSF is less volatile compared to ONTTF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check ONTTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BIESF has a market cap of 1.6B. Regarding current trading prices, IDRSF is priced at $4.32, while BIESF trades at $32.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BIESF's P/E ratio is -44.44. In terms of profitability, IDRSF's ROE is +0.10%, compared to BIESF's ROE of -0.05%. Regarding short-term risk, IDRSF is more volatile compared to BIESF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check BIESF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CSPHF has a market cap of 1.5B. Regarding current trading prices, IDRSF is priced at $4.32, while CSPHF trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CSPHF's P/E ratio is -20.20. In terms of profitability, IDRSF's ROE is +0.10%, compared to CSPHF's ROE of -0.64%. Regarding short-term risk, IDRSF is less volatile compared to CSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CSPHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, HBMHF has a market cap of 1.3B. Regarding current trading prices, IDRSF is priced at $4.32, while HBMHF trades at $1.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas HBMHF's P/E ratio is 17.33. In terms of profitability, IDRSF's ROE is +0.10%, compared to HBMHF's ROE of +0.36%. Regarding short-term risk, IDRSF is less volatile compared to HBMHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check HBMHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SNBIF has a market cap of 1.3B. Regarding current trading prices, IDRSF is priced at $4.32, while SNBIF trades at $16.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SNBIF's P/E ratio is -49.85. In terms of profitability, IDRSF's ROE is +0.10%, compared to SNBIF's ROE of -0.89%. Regarding short-term risk, IDRSF is less volatile compared to SNBIF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check SNBIF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PHGUF has a market cap of 1.2B. Regarding current trading prices, IDRSF is priced at $4.32, while PHGUF trades at $1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PHGUF's P/E ratio is -175.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to PHGUF's ROE of +0.01%. Regarding short-term risk, IDRSF is less volatile compared to PHGUF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check PHGUF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MDCLF has a market cap of 1.2B. Regarding current trading prices, IDRSF is priced at $4.32, while MDCLF trades at $34.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MDCLF's P/E ratio is -47.76. In terms of profitability, IDRSF's ROE is +0.10%, compared to MDCLF's ROE of +0.84%. Regarding short-term risk, IDRSF is more volatile compared to MDCLF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check MDCLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NURPF has a market cap of 1.1B. Regarding current trading prices, IDRSF is priced at $4.32, while NURPF trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NURPF's P/E ratio is 51.91. In terms of profitability, IDRSF's ROE is +0.10%, compared to NURPF's ROE of +0.09%. Regarding short-term risk, IDRSF is less volatile compared to NURPF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check NURPF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CSBTF has a market cap of 1.1B. Regarding current trading prices, IDRSF is priced at $4.32, while CSBTF trades at $28.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CSBTF's P/E ratio is 350.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to CSBTF's ROE of +0.02%. Regarding short-term risk, IDRSF is more volatile compared to CSBTF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check CSBTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PPTDF has a market cap of 971.7M. Regarding current trading prices, IDRSF is priced at $4.32, while PPTDF trades at $7.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PPTDF's P/E ratio is -41.78. In terms of profitability, IDRSF's ROE is +0.10%, compared to PPTDF's ROE of -0.03%. Regarding short-term risk, IDRSF is less volatile compared to PPTDF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check PPTDF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BTTAY has a market cap of 943M. Regarding current trading prices, IDRSF is priced at $4.32, while BTTAY trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, IDRSF's ROE is +0.10%, compared to BTTAY's ROE of -0.05%. Regarding short-term risk, IDRSF is more volatile compared to BTTAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check BTTAY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, TKBIF has a market cap of 879M. Regarding current trading prices, IDRSF is priced at $4.32, while TKBIF trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas TKBIF's P/E ratio is -22.12. In terms of profitability, IDRSF's ROE is +0.10%, compared to TKBIF's ROE of N/A. Regarding short-term risk, IDRSF is less volatile compared to TKBIF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check TKBIF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BPMUF has a market cap of 846.9M. Regarding current trading prices, IDRSF is priced at $4.32, while BPMUF trades at $69.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BPMUF's P/E ratio is 9.69. In terms of profitability, IDRSF's ROE is +0.10%, compared to BPMUF's ROE of +0.35%. Regarding short-term risk, IDRSF is more volatile compared to BPMUF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check BPMUF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, IVEVF has a market cap of 741.2M. Regarding current trading prices, IDRSF is priced at $4.32, while IVEVF trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas IVEVF's P/E ratio is -2.38. In terms of profitability, IDRSF's ROE is +0.10%, compared to IVEVF's ROE of +18.92%. Regarding short-term risk, IDRSF is less volatile compared to IVEVF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check IVEVF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, VBIZF has a market cap of 724.5M. Regarding current trading prices, IDRSF is priced at $4.32, while VBIZF trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas VBIZF's P/E ratio is 34.34. In terms of profitability, IDRSF's ROE is +0.10%, compared to VBIZF's ROE of +0.06%. Regarding short-term risk, IDRSF is less volatile compared to VBIZF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check VBIZF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CKDXF has a market cap of 601.9M. Regarding current trading prices, IDRSF is priced at $4.32, while CKDXF trades at $0.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, IDRSF's ROE is +0.10%, compared to CKDXF's ROE of +0.84%. Regarding short-term risk, IDRSF is less volatile compared to CKDXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CKDXF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SOLTF has a market cap of 570.1M. Regarding current trading prices, IDRSF is priced at $4.32, while SOLTF trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SOLTF's P/E ratio is -7.24. In terms of profitability, IDRSF's ROE is +0.10%, compared to SOLTF's ROE of -0.19%. Regarding short-term risk, IDRSF is more volatile compared to SOLTF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SOLTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GNFTF has a market cap of 553.4M. Regarding current trading prices, IDRSF is priced at $4.32, while GNFTF trades at $11.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GNFTF's P/E ratio is -5.47. In terms of profitability, IDRSF's ROE is +0.10%, compared to GNFTF's ROE of -5.96%. Regarding short-term risk, IDRSF is more volatile compared to GNFTF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check GNFTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, INRLF has a market cap of 542.1M. Regarding current trading prices, IDRSF is priced at $4.32, while INRLF trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas INRLF's P/E ratio is -3.94. In terms of profitability, IDRSF's ROE is +0.10%, compared to INRLF's ROE of -0.75%. Regarding short-term risk, IDRSF is less volatile compared to INRLF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check INRLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, RAONF has a market cap of 451.7M. Regarding current trading prices, IDRSF is priced at $4.32, while RAONF trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas RAONF's P/E ratio is -43.33. In terms of profitability, IDRSF's ROE is +0.10%, compared to RAONF's ROE of -0.26%. Regarding short-term risk, IDRSF is less volatile compared to RAONF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check RAONF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, GNFTY has a market cap of 447.8M. Regarding current trading prices, IDRSF is priced at $4.32, while GNFTY trades at $8.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas GNFTY's P/E ratio is -9.94. In terms of profitability, IDRSF's ROE is +0.10%, compared to GNFTY's ROE of -0.69%. Regarding short-term risk, IDRSF is less volatile compared to GNFTY. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check GNFTY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, IDRSF is priced at $4.32, while TBGNF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, IDRSF's ROE is +0.10%, compared to TBGNF's ROE of -0.01%. Regarding short-term risk, IDRSF is more volatile compared to TBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check TBGNF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PTCHF has a market cap of 428.4M. Regarding current trading prices, IDRSF is priced at $4.32, while PTCHF trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PTCHF's P/E ratio is 10.35. In terms of profitability, IDRSF's ROE is +0.10%, compared to PTCHF's ROE of +0.13%. Regarding short-term risk, IDRSF is less volatile compared to PTCHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check PTCHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CYDY has a market cap of 413.9M. Regarding current trading prices, IDRSF is priced at $4.32, while CYDY trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CYDY's P/E ratio is -7.57. In terms of profitability, IDRSF's ROE is +0.10%, compared to CYDY's ROE of +0.37%. Regarding short-term risk, IDRSF is less volatile compared to CYDY. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CYDY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NWPHF has a market cap of 399.3M. Regarding current trading prices, IDRSF is priced at $4.32, while NWPHF trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NWPHF's P/E ratio is N/A. In terms of profitability, IDRSF's ROE is +0.10%, compared to NWPHF's ROE of +16.69%. Regarding short-term risk, IDRSF is less volatile compared to NWPHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check NWPHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, AVCTF has a market cap of 390.7M. Regarding current trading prices, IDRSF is priced at $4.32, while AVCTF trades at $1.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas AVCTF's P/E ratio is -5.95. In terms of profitability, IDRSF's ROE is +0.10%, compared to AVCTF's ROE of -3.76%. Regarding short-term risk, IDRSF is more volatile compared to AVCTF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check AVCTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SLNCF has a market cap of 334.4M. Regarding current trading prices, IDRSF is priced at $4.32, while SLNCF trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SLNCF's P/E ratio is -3.75. In terms of profitability, IDRSF's ROE is +0.10%, compared to SLNCF's ROE of -3.59%. Regarding short-term risk, IDRSF is more volatile compared to SLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SLNCF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NWBO has a market cap of 321.2M. Regarding current trading prices, IDRSF is priced at $4.32, while NWBO trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NWBO's P/E ratio is -5.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to NWBO's ROE of +0.71%. Regarding short-term risk, IDRSF is less volatile compared to NWBO. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check NWBO's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CLVLY has a market cap of 318.1M. Regarding current trading prices, IDRSF is priced at $4.32, while CLVLY trades at $6.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CLVLY's P/E ratio is 13.72. In terms of profitability, IDRSF's ROE is +0.10%, compared to CLVLY's ROE of +0.13%. Regarding short-term risk, IDRSF is more volatile compared to CLVLY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check CLVLY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CLVLF has a market cap of 316.1M. Regarding current trading prices, IDRSF is priced at $4.32, while CLVLF trades at $6.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CLVLF's P/E ratio is 12.54. In terms of profitability, IDRSF's ROE is +0.10%, compared to CLVLF's ROE of +0.13%. Regarding short-term risk, IDRSF is more volatile compared to CLVLF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check CLVLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NGENF has a market cap of 312.9M. Regarding current trading prices, IDRSF is priced at $4.32, while NGENF trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NGENF's P/E ratio is -15.19. In terms of profitability, IDRSF's ROE is +0.10%, compared to NGENF's ROE of -974.60%. Regarding short-term risk, IDRSF is less volatile compared to NGENF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check NGENF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SPHDF has a market cap of 312.1M. Regarding current trading prices, IDRSF is priced at $4.32, while SPHDF trades at $22.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SPHDF's P/E ratio is -3.19. In terms of profitability, IDRSF's ROE is +0.10%, compared to SPHDF's ROE of -5.22%. Regarding short-term risk, IDRSF is more volatile compared to SPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SPHDF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, FGHQF has a market cap of 304.2M. Regarding current trading prices, IDRSF is priced at $4.32, while FGHQF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas FGHQF's P/E ratio is 15.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to FGHQF's ROE of +0.02%. Regarding short-term risk, IDRSF is more volatile compared to FGHQF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check FGHQF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, IDRSF is priced at $4.32, while PBBIF trades at $24.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, IDRSF's ROE is +0.10%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, IDRSF is more volatile compared to PBBIF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check PBBIF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ORPOF has a market cap of 260.3M. Regarding current trading prices, IDRSF is priced at $4.32, while ORPOF trades at $11.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ORPOF's P/E ratio is -11.86. In terms of profitability, IDRSF's ROE is +0.10%, compared to ORPOF's ROE of N/A. Regarding short-term risk, IDRSF is more volatile compared to ORPOF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ORPOF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ORYZF has a market cap of 258.9M. Regarding current trading prices, IDRSF is priced at $4.32, while ORYZF trades at $3.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ORYZF's P/E ratio is -83.50. In terms of profitability, IDRSF's ROE is +0.10%, compared to ORYZF's ROE of -0.03%. Regarding short-term risk, IDRSF is less volatile compared to ORYZF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check ORYZF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, HLOSF has a market cap of 247.6M. Regarding current trading prices, IDRSF is priced at $4.32, while HLOSF trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas HLOSF's P/E ratio is -13.53. In terms of profitability, IDRSF's ROE is +0.10%, compared to HLOSF's ROE of -0.80%. Regarding short-term risk, IDRSF is less volatile compared to HLOSF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check HLOSF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, HNSBF has a market cap of 245.8M. Regarding current trading prices, IDRSF is priced at $4.32, while HNSBF trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas HNSBF's P/E ratio is -4.03. In terms of profitability, IDRSF's ROE is +0.10%, compared to HNSBF's ROE of +2.02%. Regarding short-term risk, IDRSF is more volatile compared to HNSBF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check HNSBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SPHRY has a market cap of 238.7M. Regarding current trading prices, IDRSF is priced at $4.32, while SPHRY trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SPHRY's P/E ratio is -94.50. In terms of profitability, IDRSF's ROE is +0.10%, compared to SPHRY's ROE of -0.05%. Regarding short-term risk, IDRSF is less volatile compared to SPHRY. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check SPHRY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CMVLF has a market cap of 222.8M. Regarding current trading prices, IDRSF is priced at $4.32, while CMVLF trades at $3.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CMVLF's P/E ratio is -4.60. In terms of profitability, IDRSF's ROE is +0.10%, compared to CMVLF's ROE of -0.70%. Regarding short-term risk, IDRSF is more volatile compared to CMVLF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check CMVLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, CAIHF has a market cap of 217.4M. Regarding current trading prices, IDRSF is priced at $4.32, while CAIHF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas CAIHF's P/E ratio is 2.80. In terms of profitability, IDRSF's ROE is +0.10%, compared to CAIHF's ROE of +0.12%. Regarding short-term risk, IDRSF is less volatile compared to CAIHF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check CAIHF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BOVNF has a market cap of 216.4M. Regarding current trading prices, IDRSF is priced at $4.32, while BOVNF trades at $3.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BOVNF's P/E ratio is -7.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to BOVNF's ROE of -0.47%. Regarding short-term risk, IDRSF is less volatile compared to BOVNF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check BOVNF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, IDRSF is priced at $4.32, while FPHAF trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, IDRSF's ROE is +0.10%, compared to FPHAF's ROE of +0.00%. Regarding short-term risk, IDRSF is more volatile compared to FPHAF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check FPHAF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, KNTPF has a market cap of 172.1M. Regarding current trading prices, IDRSF is priced at $4.32, while KNTPF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas KNTPF's P/E ratio is -6.12. In terms of profitability, IDRSF's ROE is +0.10%, compared to KNTPF's ROE of -0.63%. Regarding short-term risk, IDRSF is more volatile compared to KNTPF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check KNTPF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ADOCY has a market cap of 170.4M. Regarding current trading prices, IDRSF is priced at $4.32, while ADOCY trades at $11.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ADOCY's P/E ratio is -3.36. In terms of profitability, IDRSF's ROE is +0.10%, compared to ADOCY's ROE of +8.60%. Regarding short-term risk, IDRSF is more volatile compared to ADOCY. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ADOCY's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SCNLF has a market cap of 147.4M. Regarding current trading prices, IDRSF is priced at $4.32, while SCNLF trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SCNLF's P/E ratio is -14.20. In terms of profitability, IDRSF's ROE is +0.10%, compared to SCNLF's ROE of +0.90%. Regarding short-term risk, IDRSF is less volatile compared to SCNLF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check SCNLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, SPHRF has a market cap of 147.3M. Regarding current trading prices, IDRSF is priced at $4.32, while SPHRF trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas SPHRF's P/E ratio is -35.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to SPHRF's ROE of -0.16%. Regarding short-term risk, IDRSF is more volatile compared to SPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check SPHRF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, TRGNF has a market cap of 144.2M. Regarding current trading prices, IDRSF is priced at $4.32, while TRGNF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas TRGNF's P/E ratio is -3.03. In terms of profitability, IDRSF's ROE is +0.10%, compared to TRGNF's ROE of -0.64%. Regarding short-term risk, IDRSF is less volatile compared to TRGNF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check TRGNF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, AMGXF has a market cap of 142.5M. Regarding current trading prices, IDRSF is priced at $4.32, while AMGXF trades at $0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas AMGXF's P/E ratio is -0.46. In terms of profitability, IDRSF's ROE is +0.10%, compared to AMGXF's ROE of -0.45%. Regarding short-term risk, IDRSF is less volatile compared to AMGXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check AMGXF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, IPHYF has a market cap of 140.7M. Regarding current trading prices, IDRSF is priced at $4.32, while IPHYF trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas IPHYF's P/E ratio is -2.31. In terms of profitability, IDRSF's ROE is +0.10%, compared to IPHYF's ROE of +5.94%. Regarding short-term risk, IDRSF is more volatile compared to IPHYF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check IPHYF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BRIBF has a market cap of 135.7M. Regarding current trading prices, IDRSF is priced at $4.32, while BRIBF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BRIBF's P/E ratio is -3.76. In terms of profitability, IDRSF's ROE is +0.10%, compared to BRIBF's ROE of -0.09%. Regarding short-term risk, IDRSF is less volatile compared to BRIBF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check BRIBF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, HBPCF has a market cap of 132.1M. Regarding current trading prices, IDRSF is priced at $4.32, while HBPCF trades at $1.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas HBPCF's P/E ratio is -43.25. In terms of profitability, IDRSF's ROE is +0.10%, compared to HBPCF's ROE of -0.37%. Regarding short-term risk, IDRSF is more volatile compared to HBPCF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check HBPCF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, IDRSF is priced at $4.32, while AAPGV trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas AAPGV's P/E ratio is N/A. In terms of profitability, IDRSF's ROE is +0.10%, compared to AAPGV's ROE of -1.24%. Regarding short-term risk, IDRSF is less volatile compared to AAPGV. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check AAPGV's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, IDRSF is priced at $4.32, while PSTTF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, IDRSF's ROE is +0.10%, compared to PSTTF's ROE of N/A. Regarding short-term risk, IDRSF is more volatile compared to PSTTF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check PSTTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, JWCTF has a market cap of 116.6M. Regarding current trading prices, IDRSF is priced at $4.32, while JWCTF trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas JWCTF's P/E ratio is -1.40. In terms of profitability, IDRSF's ROE is +0.10%, compared to JWCTF's ROE of -0.75%. Regarding short-term risk, IDRSF is less volatile compared to JWCTF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check JWCTF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, IDRSF is priced at $4.32, while EPRXF trades at $3.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, IDRSF's ROE is +0.10%, compared to EPRXF's ROE of -4.83%. Regarding short-term risk, IDRSF is less volatile compared to EPRXF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check EPRXF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, IDRSF is priced at $4.32, while ADOIF trades at $8.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, IDRSF's ROE is +0.10%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, IDRSF is more volatile compared to ADOIF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check ADOIF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MSCLF has a market cap of 96.6M. Regarding current trading prices, IDRSF is priced at $4.32, while MSCLF trades at $6.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MSCLF's P/E ratio is 2.43. In terms of profitability, IDRSF's ROE is +0.10%, compared to MSCLF's ROE of -0.70%. Regarding short-term risk, IDRSF is less volatile compared to MSCLF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check MSCLF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, NDTP has a market cap of 94.7M. Regarding current trading prices, IDRSF is priced at $4.32, while NDTP trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas NDTP's P/E ratio is -2.47. In terms of profitability, IDRSF's ROE is +0.10%, compared to NDTP's ROE of -0.33%. Regarding short-term risk, IDRSF is more volatile compared to NDTP. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check NDTP's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MLLCF has a market cap of 93.5M. Regarding current trading prices, IDRSF is priced at $4.32, while MLLCF trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MLLCF's P/E ratio is -1.19. In terms of profitability, IDRSF's ROE is +0.10%, compared to MLLCF's ROE of -0.60%. Regarding short-term risk, IDRSF is less volatile compared to MLLCF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check MLLCF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, MCURF has a market cap of 86.5M. Regarding current trading prices, IDRSF is priced at $4.32, while MCURF trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas MCURF's P/E ratio is -16.90. In terms of profitability, IDRSF's ROE is +0.10%, compared to MCURF's ROE of -1.02%. Regarding short-term risk, IDRSF is less volatile compared to MCURF. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check MCURF's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, BSEM has a market cap of 82.2M. Regarding current trading prices, IDRSF is priced at $4.32, while BSEM trades at $4.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas BSEM's P/E ratio is 5.55. In terms of profitability, IDRSF's ROE is +0.10%, compared to BSEM's ROE of -0.14%. Regarding short-term risk, IDRSF is less volatile compared to BSEM. This indicates potentially lower risk in terms of short-term price fluctuations for IDRSF.Check BSEM's competition here

IDRSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IDRSF stands at 1.1B. In comparison, PBIGF has a market cap of 81.3M. Regarding current trading prices, IDRSF is priced at $4.32, while PBIGF trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IDRSF currently has a P/E ratio of -6.55, whereas PBIGF's P/E ratio is -2.57. In terms of profitability, IDRSF's ROE is +0.10%, compared to PBIGF's ROE of -2.66%. Regarding short-term risk, IDRSF is more volatile compared to PBIGF. This indicates potentially higher risk in terms of short-term price fluctuations for IDRSF.Check PBIGF's competition here